Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Sarcoma, Endometrial Stromal 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Neoplasms by Site 1Neoplasms 1Endometrial Neoplasms 1ER+ Breast Cancer 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

Tamoxifen 5Specimen Handling 4exemestane 2Letrozole 2Anastrozole 2fezolinetant 1elacestrant 1Testosterone 1Surgical Procedures, Operative 1Omacor 1Neoadjuvant Therapy 1FAPI-46 1Biopsy 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × elacestrant × 30 days × Clear all
NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡